This article outlines Aixial’s comprehensive best practices for operational oversight of safety system lifecycle management.

At Aixial, we conducted up to 150 neurological studies, up to 300 oncology trials in various geographical areas such as Europe, North America, Asia Pacific, thus giving us the opportunity to oversee what works and what doesn’t work in this field.

Expertise, Scale, and Trust in First-in-Human and Early Development At Aixial, we believe early phase trials—especially first-in-human (FIH) studies—set the…

Sarcomas are a diverse and rare group of malignant tumors arising from mesenchymal tissues, including bone, muscle, fat, and connective tissue.

Q&A with Aixial’s experts at ASCO 2025. Learn how we can drive success in complex oncology trials. Find us at Booth #27150.

On April 11, World Parkinson’s Day, we are reminded of the importance of research in improving treatments and finding a cure.

In the European Union, a rare disease is defined as one affecting fewer than 5 out of 10,000 members of the general population…

Honor women’s significant achievements in science and place a much-needed focus on girls entering Science, Technology, Engineering, and Mathematics (STEM) careers.

Ashley Hunter and Anna Yanaeva led an engaging discussion on the importance of “Utilising CROs for Effective Planning and Execution of Clinical Development”.

Clear communication is essential to drug development. At Aixial Group, our experienced medical writers know how to turn complex scientific data into clear, accurate documents.